UK clinical AI technology company, Sensyne Health (SENS) announced on Thursday that it had extended its existing collaboration with multinational pharmaceutical firm, Bayer, for the development of new treatments using clinical AI.
Sensyne will partner with Bayer’s division, LifeHub UK, which makes up a wider network of global innovation hotspots with the aim of catalysing impactful solutions at the intersection of health and nutrition.
Specifically, the division, which launches today, is designed to streamline disease detection as well as data-driven drug discovery with the aid of AI-enabled imaging solutions.
Commenting on the extended collaboration, CEO of Sensyne Health, Lord Paul Drayson explained, "Initiatives like this are essential to quickly maximise the opportunity AI presents to improve patient care and accelerate medical research.”
Sensyne will be one of the first companies to establish a presence in the LifeHub, with the first project focusing on radiology solutions using the firm’s AI technology platform in order to identify digital solutions for automated image evaluation.
The project will analyse research from three million anonymised, ethically sourced NHS patient records and data provided through Sensyne’s partnerships with NHS trusts, with the NHS remaining the controller of all patient data.
Essentially, Sensyne will act as a ‘docking station’ for anonymised patient data analysis under strict oversight from the NHS trust, the company emphasised -- this will ensure ethical governance is practiced under NHS principles, EU data protection law and regulatory guidance.
Kemal Malik, a Bayer Board Member for Innovation, expressed his delight at the programme, stating that its launch reflected a firm belief in the transformative potential of AI in healthcare, he commented:
"LifeHub UK's roadmap is a perfect fit to Bayer's Open Innovation strategy, which is designed to leverage places, programmes and partnerships - such as strategic alliances and joint ventures - in the life sciences fields of pharmaceuticals and agriculture."
Additionally, the firm revealed its intentions to conduct further joint R&D activities with Bayer to further advance imaging solutions using AI.
Follow News & Updates from Sensyne Health here: